Real-time Quotes | Nasdaq Last Sale

After Hours: 17.04 0 0.00% 19:56 12/04 EST
Corp Actions
PIMCO Closed-End Funds Declare Monthly Common Share Distributions
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below. The distributions are payable on January 4, 2021 to shareholders of record on December 11, 2020, with an ex-dividend date of December 10, 2020.  Monthly Distribution Per Share FundNYSE SymbolAmountChange From Previous MonthPercentage Change From Previous Month PIMCO Corporate & Income Strategy Fund(NYSE: PCN)$0.112500-- PIMCO Corporate & Income Opportunity Fund(NYSE: PTY)$0.130000-- PIMCO Global StocksPLUS® & Income Fund(NYSE: PGP)$0.069000-- PIMCO High Income Fund(NYSE: PHK)$0.048000-- PIMCO Income Opportunity Fund(NYSE: PKO)$0.190000-- PIMCO Strategic Income Fund, Inc.(NYSE: RCS)$0.051000-- PCM Fund, Inc.(NYSE: PCM)$0.080000-- PIMCO Income Strategy Fund(NYSE: PFL)$0.090000-- PIMCO Income Strategy Fund II(NYSE: PFN)$0.080000-- PIMCO Dynamic Income Fund(NYSE: PDI)$0.220500-- PIMCO Dynamic Credit and Mortgage Income Fund(NYSE: PCI)$0.174000-- PIMCO Municipal Income Fund(NYSE: PMF)$0.054000-- PIMCO California Municipal Income Fund(NYSE: PCQ)$0.065000-- PIMCO New York Municipal Income Fund(NYSE: PNF)$0.042000-- PIMCO Municipal Income Fund II(NYSE: PML)$0.059000-- PIMCO California Municipal Income Fund II(NYSE: PCK)$0.032000-- PIMCO New York Municipal Income Fund II(NYSE: PNI)$0.040045-- PIMCO Municipal Income Fund III(NYSE: PMX)$0.046000-- PIMCO California Municipal Income Fund III(NYSE: PZC)$0.038000-- PIMCO New York Municipal Income Fund III(NYSE: PYN)$0.035490-- Distributions from PMF, PML, PMX, PCQ, PCK, PZC, PNF, PNI and PYN are generally exempt from regular federal income taxes. In addition, distributions from PCQ, PCK and PZC are also generally exempt from California state income taxes, and distributions from PNF, PNI and PYN are generally exempt from New York State and city income taxes. There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.Distributions may include ordinary income, net capital gains and/or returns of capital. Generally, a return of capital occurs when the amount distributed by a Fund includes a portion of (or is comprised entirely of) your investment in the Fund in addition to (or rather than) your pro-rata portion of the Fund’s net income or capital gains. A Fund’s distributions in any period may be more or less than the net return earned by the Fund on its investments, and therefore should not be used as a measure of performance or confused with “yield” or “income.” A return of capital is not taxable; rather it reduces a shareholder’s tax basis in his or her shares of the Fund.To the extent required by the 1940 Act and other applicable laws, absent an exemption, a notice will accompany each monthly distribution with respect to the estimated source (as between net income, gains or other capital source) of the distribution made. If a Fund estimates that a portion of one of its dividend distributions may be comprised of amounts from sources other than net income, in accordance with its policies and good accounting practices, the Fund will notify shareholders of record of the estimated composition of such distribution through a Section 19 Notice. For these purposes, the Fund estimates the source or sources from which a distribution is paid, to the close of the period as of which it is paid, in reference to its internal accounting records and related accounting practices. If, based on such accounting records and practices, it is estimated that a particular distribution does not include capital gains or paid-in surplus or other capital sources, a Section 19 Notice generally would not be issued. It is important to note that differences exist between the Fund’s daily internal accounting records and practices, the Fund’s financial statements presented in accordance with U.S. GAAP, and recordkeeping practices under income tax regulations. For instance, the Fund’s internal accounting records and practices may take into account, among other factors, tax-related characteristics of certain sources of distributions that differ from treatment under U.S. GAAP. Examples of such differences may include, among others, the treatment of paydowns on mortgage-backed securities purchased at a discount and periodic payments under interest rate swap contracts. Accordingly, among other consequences, it is possible that the Fund may not issue a Section 19 Notice in situations where the Fund’s financial statements prepared later and in accordance with U.S. GAAP and/or the final tax character of those distributions might later report that the sources of those distributions included capital gains and/or a return of capital. Please see the Funds' most recent shareholder reports and Section 19 Notice, if applicable, for more details.A Fund’s distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that a change in market conditions or other factors will not result in a change in a Fund’s distribution rate at a future time.The tax treatment and characterization of a Fund's distributions may vary significantly from time to time because of the varied nature of the Fund's investments. For example, a Fund may enter into opposite sides of multiple interest rate swaps or other derivatives with respect to the same underlying reference instrument (e.g., a 10-year U.S. treasury) that have different effective dates with respect to interest accrual time periods for the principal purpose of generating distributable gains (characterized as ordinary income for tax purposes) that are not part of the Fund's duration or yield curve management strategies. In such a "paired swap transaction", the Fund would generally enter into one or more interest rate swap agreements whereby the Fund agrees to make regular payments starting at the time the Fund enters into the agreements equal to a floating interest rate in return for payments equal to a fixed interest rate (the "initial leg"). The Fund would also enter into one or more interest rate swap agreements on the same underlying instrument, but take the opposite position (i.e., in this example, the Fund would make regular payments equal to a fixed interest rate in return for receiving payments equal to a floating interest rate) with respect to a contract whereby the payment obligations do not commence until a date following the commencement of the initial leg (the "forward leg"). Certain Funds may engage in investment strategies, including those that employ the use of derivatives, to, among other things, seek to generate current, distributable income, even if such strategies could potentially result in declines in the Fund's net asset value. The Fund's income and gain-generating strategies, including certain derivatives strategies, may generate current income and gains taxable as ordinary income sufficient to support monthly distributions even in situations when the Fund has experienced a decline in net assets due to, for example, adverse changes in the broad U.S. or non-U.S. equity markets or the Fund's debt investments, or arising from its use of derivatives. Because some or all of these transactions may generate capital losses without corresponding offsetting capital gains, portions of the Fund's distributions recognized as ordinary income for tax purposes (such as from paired swap transactions) may be economically similar to a taxable return of capital when considered together with such capital losses. The tax treatment of certain derivatives in which the Fund invests may be unclear and thus subject to recharacterization. Any recharacterization of payments made or received by the Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions. In addition, the tax treatment of such investment strategies may be changed by regulation or otherwise.The common shares of the Funds trade on the New York Stock Exchange. As with any stock, the price of a Fund’s common shares will fluctuate with market conditions and other factors. If you sell your common shares of a Fund, the price received may be more or less than your original investment.Shares of closed-end investment management companies, such as the Funds, frequently trade at a discount from their net asset value and may trade at a price that is less than the initial offering price and/or the net asset value of such shares. Further, if a Fund’s shares trade at a price that is more than the initial offering price and/or the net asset value of such shares, including at a substantial premium and/or for an extended period of time, there is no assurance that any such premium will be sustained for any period of time and will not decrease, or that the shares will not trade at a discount to net asset value thereafter.The Funds’ daily New York Stock Exchange closing market prices, net asset values per share, as well as other information, including updated portfolio statistics and performance are available at or by calling the Funds’ shareholder servicing agent at (844) 33-PIMCO. Updated portfolio holdings information about a Fund will be available approximately 15 calendar days after such Fund’s most recent fiscal quarter end, and will remain accessible until such Fund files a Form N-PORT or a shareholder report for the period which includes the date of the information.About PIMCOPIMCO was founded in 1971 in Newport Beach, California and is one of the world’s premier fixed income investment managers. Today we have offices across the globe and 2,800+ professionals united by a single purpose: creating opportunities for investors in every environment. PIMCO is owned by Allianz S.E., a leading global diversified financial services provider.Except for the historical information and discussions contained herein, statements contained in this news release constitute forward-looking statements. These statements may involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including the performance of financial markets, the investment performance of PIMCO's sponsored investment products and separately managed accounts, general economic conditions, future acquisitions, competitive conditions and government regulations, including changes in tax laws. Readers should carefully consider such factors. Further, such forward-looking statements speak only on the date at which such statements are made. PIMCO undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statement.This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. PIMCO is a trademark of Allianz Asset Management of America L.P. in the United States and throughout the world. ©2020, PIMCOFor information on PIMCO Closed-End Funds: Financial Advisors: (800) 628-1237 Shareholders: (844) 337-4626 or (844) 33-PIMCO PIMCO Media Relations: (212) 597-1054
GlobeNewswire · 3d ago
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 6d ago
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.
GlobeNewswire · 11/25 12:04
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. TTI-622: Poster Presentation, Publication Number 1191 Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I Date: Saturday, December 5, 2020; available from 10:00AM EST TTI-621: Oral Presentation, Publication Number 646 Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies Presenter: Steven M. Horwitz, M.D., Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell Lymphoma Date: Monday, December 7, 2020; Presentation at 3:00PM ESTThe presentations will be available in the Events & Presentations section of Trillium’s website once released by the American Society of Hematology.Trillium will host a conference call on Monday, December 7th at 4:30PM EST.International Dial-In Number: +1 236-389-2162 Conference ID: 3169183Webcast link: Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.For more information visit: Investor Relations: James Parsons Chief Financial Officer Trillium Therapeutics Inc. 416-595-0627 x232  Media Relations: Mike Beyer Sam Brown Inc. 312-961-2502
GlobeNewswire · 11/25 12:00
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
Cancer-Fighting Biotechs Jump 1,000% in Shadow of Covid Stocks
(Bloomberg) -- A pair of biotech companies fighting yet another modern disease - cancer - have seen their shares soar over 1,000% this year.Investors’ optimism on promising results on cancer-fighting platforms by Cardiff Oncology Inc. and Trillium Therapeutics Inc. has propelled the duo to the group of five best performers in the Nasdaq Composite Index of nearly 3,000 stocks. While Covid-19 has dominated headlines, boosting shares of companies involved in vaccines, cancer therapies and even treatments for easily-spread bacterial infections remain an area for investors to make millions.Trillium has skyrocketed 1,606% this year, while Cardiff rallied 1,244%. Seres Therapeutics Inc., which is developing drugs for common bacterial infections and ulcerative colitis, surged 829%. Trillium, the best performer of the three, only lags Novavax Inc., which has ridden a wave of euphoria following the development of its experimental Covid-19 vaccine.The pickup in trading volume is almost as impressive. Investors have daily traded over 1 million shares of Seres and Trillium. That compares with 1.1 million shares for industry heavyweights Regeneron Pharmaceuticals Inc. and 1.8 million shares for Biogen Inc.Biotech Nerd“There are a lot of other technologies that are really transforming medicines that are very powerful and also very valuable,” said Brad Loncar, chief executive officer at Loncar Investments. “Unless you’re a biotech nerd like we are and follow it every day, you might not know about it because what’s happening with vaccines and treatments is only the tip of the iceberg in terms of helping patients and moving stocks in the biotech sector.”However, biotechnology stocks are anything but sure bets. None of the three companies have successfully brought a drug to market and face key catalysts that will dictate their success in the coming weeks and months.Impending CatalystsCardiff, based in San Diego, has undergone a renaissance after changing its name from Trovagene and placing Mark Erlander at the helm of the company back in May. The CEO quickly struck a pact to fund a mid-stage study of the company’s lead drug onvansertib for colon cancer, winning support from industry heavyweights like RA Capital Management LLC and Venrock Partners Management V LLC.While it has only four sell-side analysts covering the stock, the firm is a unanimous buy with the average analyst price target implying shares could run another 64% over the coming year. Cardiff’s lead program in colon cancer represents “an area of serious unmet need,” according to HC Wainwright analyst Raghuram Selvaraju. Data from a study of the company’s combination trial are expected to come at a medical meeting in January and could move shares further, he said.For Trillium investors that have stuck with its revival led by chief executive Jan Skvarka, the payout has been massive. The stock has surged 4,550% since Skvarka joined the company last September and is the top stock by a mile on Canada’s S&P/TSX Composite Index this year -- skyrocketing past tech behemoth Shopify Inc. and a bevy of gold miners by more than tenfold.The next catalyst for the Cambridge, Massachusetts-based biotech firm will be updated results from a pair of cancer drugs at the American Society of Hematology meeting next month. Promising data have been the key driver of the stock’s surge and fresh results could spark a move higher, according to analysts.Seres, which is also based in Cambridge, was transformed in August when it reported promising data from a study of its medicine as a treatment for bacteria-caused colon infection, known as C. difficile colitis. The results sparked a 389% one-day rally. The advancement of the company’s broader pipeline will be key going into 2021, according to analysts.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 11/20 12:15
The Daily Biotech Pulse:Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17)
Benzinga · 11/18 12:29
Trillium Therapeutics reports 9M results
Trillium Therapeutics (TRIL): 9M GAAP EPS of -$2.19.Revenue of $0.11M (-35.3% Y/Y)Press Release
Seekingalpha · 11/16 12:12
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRIL. Analyze the recent business situations of TRILLIUM THERAPE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRIL stock price target is 21.50 with a high estimate of 28.00 and a low estimate of 14.00.
Institutional Holdings
Institutions: 139
Institutional Holdings: 72.93M
% Owned: 72.67%
Shares Outstanding: 100.36M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
President/Chief Executive Officer/Director
Jan Skvarka
Chief Financial Officer/IR Contact Officer
James Parsons
Chief Scientific Officer
Robert Uger
Ingmar Bruns
Penka Petrova
Ali Behbahani
Michael Kamarck
Paolo Pucci
Independent Director
Paul Walker
Non-Executive Independent Director
Luke Beshar
Non-Executive Independent Director
Thomas Reynolds
Non-Executive Independent Director
Helen Tayton-Martin
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TRIL
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Hot Stocks

Webull offers kinds of Trillium Therapeutics Inc stock information, including NASDAQ:TRIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRIL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRIL stock methods without spending real money on the virtual paper trading platform.